WWW.ZUELLIGPHARMA.

COM

DI S T R I B U T I O N &
C L I EN T S ERV I C ES

C A RECONNECT
COM MER C I A L
S O LU T I O N S

CL I N I C A L
R EAC H

D IGITAL
DATA
A N A LY T I C S

S US TA I N A B I L I T Y

making healthcare more accessible

Zuellig Pharma
Ecosystem
CARECONNECT

CLIN ICAL
REACH

D IG I TA L

IMP R OV IN G
H E A LT H
O U TCOME S

SU STA IN ABI LI TY

S E T T IN G T H E
H IG H E S T S TA N DA R D S
O F IN T EG R IT Y
D IS T RIBUTION &
CLIENT SERVICES

COMMERCIAL
SOLUT ION S

Women’s Health
Diabetes / Specialty
Consumer Health

DATA
ANALY TICS

NU RT U R I N G R E S P EC T IN G T H E
TA LE N T E N V IR ONME N T

Making Healthcare
More Accessible
 ZUELLIG
PHARMA

CONTENTS
 3 C EO W E LCO M E

4 AB O U T Z U E L L I G P H AR M A

6 O U R M I S S I O N , O U R S E RV I C ES

8 O U R P EO P L E , O U R VALU ES

10 ST R U CT U R E D FO R G R OW T H

14 ACC ES S TO HE ALT HCAR E

18 S U STAI N AB I L I T Y AT
Z U E L L I G P HAR M A

26 AL L AB OAR D T H E CO L D C H AI N

30 HOW W E P R E V E N T E D A LO G I ST I CA L
LO C K D OW N TO O U R S U P P LY C H A I N

36 HOW S U P P LY C H AI N S W I L L E VO LV E
I N T HE WAK E O F COV I D -1 9

40 PAV I N G T H E WAY FO R
AG I N G P O P U L AT I O N

44 S P R I N G B OAR D I N G T H E
N E X T L E AP

46 ACC E L E RAT E G R OW T H W I T H
N E W P L AYE R S I N H E ALT HCAR E

48 T HE B LO C KC HAI N T HAT
K E E P S U S SAF E

52 DATA AN ALYT I C S I N N U M B E RS
CEO Welcome CEO Welcome

2020 has changed everything. As I step into my new role a

keeps me going is witnessing the sheer determination and

2020
has changed
front liners around the world, including Zuellig Pharma emp
when needed. This was “ZP United in Action”.
everything. As I In this issue, you will also read about how we
As we put together this annual report, I decided to dedica
step into my new helped to prevent a logistical lockdown of our supply
role as CEO during this challenging time, chain andliners.
how the I want
industryto willthank
continuethem on inbehalf of everyone who be
to evolve
what keeps me going is witnessing the sheer the wake important
of COVID-19.role in ensuring
You can find out howwe continue to bring essential he
Zuellig
determination and commitment demonstrated by Pharmaan organisation, we have united around our longstandin
has accelerated the launch of several digital
the many front liners around the world, including products designed to alleviate the constraints imposed
accessible, aiming to diminish the impact of the pandemic on
Zuellig Pharma employees. by the pandemic. We have a special section on
As we put together this annual report, WhenanCOVID-19
sustainability, area which will erupted,
be a focuswe took
for us as weimmediate steps to ensur
I decided to dedicate this issue to our Zuellig move into the new normal. As the world goes through
supplies such as ventilators and Personal Protective Equipm
Pharma front liners. I want to thank them on tremendous change, it is more important than ever
behalf of everyone who benefits from their
to those who needed them, despite travel restrictions an
to ensure that sustainability remains at the forefront
service. They all play an important role in ensuring of how worked
we conductwith the Air
our business, Force
improve to air freight lifesaving medica
healthcare,
we continue to bring essential healthcare to our 13 nurturedifficult
our talent and to look
access.
after the More than 2,000 employees came tog
environment.
markets across Asia. As an organisation, we have company,
Over the nextto fewfulfil
years,critical
my goal operations
is to roles such as picking, p
united around our longstanding purpose of making transform Zuellig Pharma into a major integrated
“ZP United in Action”.
healthcare more accessible, aiming to diminish healthcare business that is indispensable to industry
the impact of the pandemic on patients and the stakeholders. We will continue to further define our
In this issue, you will also read about how we helped to pr
people who serve them. mission through world-class, innovative solutions
When COVID-19 erupted, we took
chain and how the industry will continue to evolve in the w
in distribution, commercial solutions and patient
immediate steps to ensure that essential medicines Zuellig
care, while heavilyPharma has accelerated
leveraging digital technology. The the launch of several dig
and healthcare supplies such as ventilators and constraints
focus will imposed
be on future proofi ng our by thechain
supply pandemic. We have a special se
Personal Protective Equipment (PPE) continued be a focus for us as we move into the new normal. As the w
by digitalising, embedding our remote working
to be made available to those who needed them, capabilities, establishing platforms and fully engaging
is more important than ever to ensure that sustainability rem
despite travel restrictions and closed borders. with various stakeholders to manage potential
In the Philippines, we worked with the Air Force
our business, improve healthcare, nurture our talent and loo
disruptions and risks.
to air freight lifesaving medication to regions in These are extraordinary times, but I am certain
Over the next few years, my goal is to transform Zuellig Ph
the country that were difficult to access. More it can only make us stronger. I look forward to continue
than 2,000 employees came together from all business
partnering with eachthat is indispensable
and every one of you to buildto aindustry stakeholders. We w
departments across the company, to fulfil critical through
better and healthierworld-class, innovative
future for our communiti es. solutions in distribution, com
operations roles such as picking, packing or delivery Stay safe and take care.
heavily leveraging digital technology. The focus will be o
digitalising, embedding our remote working capabilities, e
with various stakeholders to manage potential disruptions a

These are extraordinary times, but I am certain it can only ma

partnering each and every one of you to build a better and h

Stay safe and take care.

John Graham
CEO Zuellig
JOHN GRAHAMPharma
CEO ZUELLIG PHARMA
4

OUR PAYOR BUSINESS

SERVES OVER

10.9
MILLION
MEMBERS IN
MALAYSIA, THAILAND
AND THE PHILIPPINES

About
Zuellig Pharma
Zuellig Pharma is one of the largest healthcare services groups
in Asia and our purpose is to make healthcare more accessible.
We provide world-class distribution, digital and commercial
services to support the growing healthcare needs in this region.
The company started almost a hundred years ago and
has grown to become a US$13 billion business covering 13
markets with 12,000 employees. We serve over 350,000 medical
facilities and work with more than 500 clients, including the top
20 pharmaceutical companies in the world.
More recently, we launched our Zuellig Health Solutions
Innovation Centre to develop new services and address some
pressing healthcare needs in Asia. Since then, our teams have
been focused on creating data, digital and disease management
solutions, supporting patients with chronic conditions and
helping payors manage healthcare costs.

making healthcare more accessible

 5

13
PRESENT IN
SUPPORTS OVER

2,200
COUNTRIES CLINICAL
IN ASIA TRIALS

WORKS WITH THE

TOP 20
PHARMACEUTICAL
70
COMPANIES WAREHOUSES
ACROSS THE REGION

EMPLOYS OVER 53%

12000
MALE

47%
FEMALE
REPRESENTATION IN
EMPLOYEES OUR MANAGEMENT

WWW.ZUELLIGPHARMA.COM
6

Our Mission

As one of the largest healthcare services groups in

Asia, we will continue to grow by being true to our
mission of making healthcare more accessible. Since
2015, we have been on a journey of transformation
to bring new solutions to the industry, building on
our capabilities as a specialist healthcare distributor.

Our focus in Asia makes
us familiar with its diverse
culture and needs.
We tap into our strong
local network of healthcare
facilities, professionals and
regulators for reliable market
intelligence to stay on top
of the evolving healthcare
environment.
Our reputation is built on our
commitment to compliance
and quality.
We own and operate some of
the most advanced cold chain
facilities that safely manage
temperature-sensitive
medicines. Our teams are
proud of our values and how
we operate with integrity.
We provide progressive
solutions to meet changing
healthcare needs.
The Zuellig Health Solutions
innovation centre pioneers
new ways to address
healthcare challenges
including data analytics,
commercial services, and
patient and payor services.

making healthcare more accessible


Our Services
CLINICAL REACH
We provide end-to-end clinical supply
chain solutions to ensure clinical trials
and research run smoothly
• Clinical Research Planning
& Design
• Clinical Trial Supplies
& Logistics
• Clinical Research Technology
Solutions
• Clinical Research Compliance &
Quality Management
DATA ANALYTICS
Through our analytics, we help to
deliver targeted insights that drive
growth and performance in key
therapeutic areas
• Market Intelligence
• Analytics Advisory
COMMERCIAL
SOLUTIONS
We launch and grow pharmaceutical
products through agile sales and
marketing models, and local trade
channel expertise
• Brand Development
• Lifecycle Management
• Regulatory Affairs Services
• Business Intelligence
• Market Research
• Medical Marketing
• Pharmacovigilance
DISTRIBUTION
Our end-to end solutions and
extensive distribution network
provide access to all relevant
channels in even the most remote
areas of Asia
• Transportation
• Pick & Pack
• Warehousing
• Redressing
• Cold Chain Solutions
7
CARECONNECT
PAYOR SERVICES
Our payor services help companies
and insurers develop plans and
programmes to deliver high
quality healthcare while
minimising administrative work
and managing cost
• Administration
• Cost Management
• Solutions and Interventions
• Data Insights and Advisory
PATIENT CARE
We provide innovative healthcare
solutions that encourage
healthier lifestyles, drive
prescription adherence and
improve health outcomes
• Patient Education & Public
Awareness
• Affordability Solutions
• Disease Management & Patient
Engagement Programmes
• Mass Vaccinations
WWW.ZUELLIGPHARMA.COM
8

48
27
Different
Nationalities Participants from
the Young Talent
Programme

Growing through transformati on

We believe in managing careers, not jobs.
This mantra underpins our performance

Our People
In 2015, Zuellig Pharma embarked on a journey
to transform the way we make healthcare more
accessible in Asia. This change saw shifts in our
structure, our services and correspondingly, the
different types of talent we need to drive this change.
development framework that includes
Individual Development Plans and 8 Quarter
Plans, where selected talent have career
development profi les that start with a
realisti c view of their current capabiliti es
and a roadmap to realise their aspirati ons
for the future.
With changes come new opportunities
for development. Through our Zuellig
Pharma Mobility Programme, we work with
our talents to successfully place them in roles
that give them exposure to other countries,
functions and business units.

OUR VALUES Integrity BUILD PARTNERSHIPS

INTERNALLY AND

& Trust EXTERNALLY

BUILD OPEN HONEST

RELATIONSHIPS
Collaboration

making healthcare more accessible

 9

38%
48
of Total Workforce are
Long Serving Employees
(5 years and above)

Participants from the

Advanced Management
Programme

Engaged in meaningful work

Despite going through a time of change,
Duration of the longest
our business-wide Sustainable Employee
serving employee

Engagement Score has continued to improve
by 2% year on year since 2013. Through
various focus groups and the Employee
Opinion Survey, we know that most of
our employees are here because they are
passionate and believe in our mission to
make healthcare more accessible. Performing
meaningful work every day, no matter what
the role, is the driving force behind our
improving levels of engagement.
Our reputation as a partner that
values quality and conducts itself with
integrity has been the cornerstone of our
success. This is something that we are proud
to say is true of the way we act internally as
well. Our Code of Conduct ensures a culture
of openness with the highest standards
of probity and accountability through a
‘Speak Up” Policy. We have also designed
channels to ensure that employees raise
serious concerns without fear of retaliation,
discrimination or any forms of harassment.
46
years of
service
Our employees are
here because they
are passionate and
believe in our mission
to make healthcare
more accessible.
A culture that encourages learning
As we continue to manage our diverse, multi-
generational team, one of the key strengths
is in our desire to develop talent. We run
in-house training that teaches coaching skills,
team collaboration, as well as how to be an
effective manager.
We have region-wide training
programmes such as the Young Talent and
Advanced Management Programmes that
create opportunities for employees to be
mentored by Executive Team members and
Department Heads. Our e-Learning platform
provides free certification programmes and
relevant courses to all our employees. We also
offer an Employee Development Sponsorship
Programme that provides financial support
for employees to pursue training or part-time
courses of their choice.

Innovation BE DETERMINED TO
DELIVER ONLY THE BEST Personal
BE CREATIVE AND
OPEN-MINDED Passion for Growth
Excellence PURSUE PROGRESS
AND LEARNING

WWW.ZUELLIGPHARMA.COM
10

Structured for
Growth

Zuellig Pharma has consistently built a business

that delivers operational efficiency while
being able to stand the test of time. Given the
opportunities and gaps we see in healthcare
today, our approach is now to defend and expand
Distribution, scale up Solutions and drive Digital.
We speak to three executives who have been
spearheading Asia-wide divisions for a download
on where they see opportunities in the time ahead.

making healthcare more accessible


Tom Vanmolkot
EXECUTIVE VICE PRESIDENT
DISTRIBUTION & CLIENT SERVICES
In future, we will see
many more uses of
blockchain to help us
with various checks
like temperature
excursions.
Tell us more about your new role
at Zuellig Pharma.
Tom: I started with sales, business
development and operations roles in
Vietnam, before heading up our businesses
in Korea and later North Asia. Most recently,
I led our Client Development division at the
group level. My current role is to strengthen
our focus and sharpen the execution of
our distribution business, which forms the
very core of our operations. This involves
tightening market efforts with our Area
Directors, rolling out new data and digital
tools to support our clients and strengthening
our relationships with them.
What keeps you going?
Tom: Every market is unique, and I’m proud
to work for a business that understands the
intricacies by hiring great local talent. What
keeps me going is seeing how our people,
from diverse backgrounds, are strongly
unified on our purpose to make healthcare
more accessible in Asia. Our teams have
contributed significantly to this area and as
we keep transforming, we have many future
opportunities to continue doing so.
11
Share your predictions for
the healthcare industry in the
coming year.
Tom: Actionable data will help companies
make real-time decisions that boost business
performance. The ability to track customer
purchase patterns and inform stock decisions
instantly helps to optimise supply chains.
For instance, increasing the supply of flu
medications at specific pharmacies during flu
season, will immediately address patient needs
and ensure more efficient resource allocation.
We will see more technology being
used throughout the entire distribution
journey. Automating warehouse operations,
having oversight of consignments in real-time
and optimising delivery routes all contribute
to prompt and seamless deliveries. For drugs
that are temperature sensitive, innovations
in cold chain management from packaging to
equipment will help us reach more people in
remote areas.
We’ve seen developments in the
use of blockchain to trace drugs and ensure
patients are consuming authentic products.
In future, we will see many more uses of
blockchain to help us with various checks like
temperature excursions.
What are your most important
priorities for 2020?
Tom: My priority is to continue ensuring
smooth and excellent operations in our
core services, while experimenting with
new ways to revolutionise processes. Our
team also anticipates new partnerships with
like-minded clients who will join our existing
clients that are working with us to improve
access to healthcare.
WWW.ZUELLIGPHARMA.COM
12
John Graham
CEO & EXECUTIVE VICE PRESIDENT
COMMERCIAL SOLUTIONS
You’ve been in the industry for
37 years, tell us more about your
experience.
John: I came into Zuellig Pharma as SVP
for Commercial Solutions in 2018 with
rich experience in the Pharmaceutical and
Biotechnology industry. This involved a host
of roles from senior operations to C-suite
strategic advisory. I’ve supported the success
of multiple organisations and start-ups and
had the chance to live and work across the
globe. Every day in healthcare is enriching.
While the climate can be complex and
litigious, the benefit of bringing healthcare to
the unreached always reignites my passion to
continue in the industry.
making healthcare more accessible
What can we look forward to from
Digital experiences Commercial Solutions in 2020?
John: This year, our priorities include driving
have become an our Women’s Health and Consumer Health
portfolio to various markets. We will continue
expectation from to engage healthcare professionals and
consumers and clients. drive conversations to support the medical
community in making more developments
in these areas. The team is also looking
What are your predictions for forward to growing our clients’ products
the healthcare industry in the across diverse categories to ensure patients
coming year? get access to the healthcare they need.
John: The rise of Femtech - products, apps More specifically, we are also very excited
and hardware that address women’s health about our Diabetes & Specialty treatment
and wellbeing - will lead to greater awareness portfolio with innovative medicines in the
amongst organisations on the need to focus areas of diabetes, oncology, men’s health,
resources on women’s health. Today we see bone health, diseases impacting the central
dedicated digital resources and tools tailored nervous system and immunology.
towards women to provide insights on
conditions like uterine fibroids and its various
treatment options. We’re also a long-term
partner with many manufacturers who are
bringing innovative healthcare to Asia and we
expect many great products we can help to
represent in our markets.
Digital experiences have become an
expectation from consumers and clients.
This extends to healthcare professionals
who are tapping on the medical
e-community to inform their decisions
and receive the latest information on new
products and interventions.

Tell us more about your current
role as SVP CareConnect.
Moses: CareConnect is made up of
PatientCare and payor services. Leading the
team, I work with regional and in-market
colleagues to oversee the development
of integrated healthcare and healthcare
administration services that deliver value to
clients, payors and patients.
Share about your experience in
leading CareConnect for the past
7 years.
Moses: CareConnect has come a long way
from humble beginnings. Our goal has
always been to provide innovative healthcare
delivery and cost management solutions
that encourage healthier lifestyles, drive
adherence and manage healthcare costs. Our
PatientCare services have increased patient
adherence rates by 300% and our payor
business serves almost 11 million members in
Malaysia, Thailand and the Philippines today.
Moses Hee These are results of the team’s relentless
SENIOR VICE PRESIDENT efforts, which have also contributed to
CARECONNECT continual growth over the years.
13
Share your predictions for
the healthcare industry in the
coming year.
Moses: In light of the COVID-19 situation,
governments and healthcare entities will
review their response efforts and channel
more resources into preparing communities
for pandemics. This includes updating
preparedness plans and checklists. We will
also start to see more campaigns and public
health materials being rolled out to raise
awareness about pandemics and suggest
ideal community responses in different
situations. On digital healthcare, patients
will be able to get even more out of mobile
applications - from detecting diabetic
retinopathy through retina scans to charting
glucose levels in their blood - so we predict
plenty of development in this area from
software to hardware and partnerships within
the healthcare ecosystem.
What can we look forward to
from CareConnect in 2020?
Moses: In 2020, we are looking to grow the
membership base of our payor business and
bring our services to more markets. We will
also be focusing on the launch of our first
integrated pharma-payor programme. We
also prioritised the development of platforms
like i-Switch+ which supports patient access
and affordability programmes by helping
patients manage the cost of their long term
medication. This allows HCPs to easily track
patients’ rebates and provide alerts when
they are entitled to free medication.
Soon, patients will
be able to get even
more out of mobile
applications.
WWW.ZUELLIGPHARMA.COM
14

Access
TO
Healthcare
Delivering our purpose by harnessing the best of our history and technology

making healthcare more accessible


A
geing populations, changing patient expectations
and the evolving burden of disease, are key
contributors to rapidly increasing healthcare costs.
Asia, that has long been affected by infectious
diseases, is now also combatting a significant
rise in chronic illnesses, like diabetes and cardiovascular disease.
Despite massive efforts, many large rural populations still struggle
to access healthcare services, due to underdeveloped infrastructure
and a lack of healthcare professionals.
Finding solutions to these complex issues requires
collaboration between many parties, from the public and private
sectors. Given our unique position in the industry, Zuellig Pharma
has been serving as a connector to drive collaboration across the
healthcare ecosystem so that more parties can be involved to bring
quality health services to anyone who needs it.
15
Bringing healthcare to remote populations
According to the World Bank and World Health
Organization (WHO), half the world still lacks access to
essential health services and 100 million people are still
pushed into extreme poverty because of health expenses.
This explains why one of the United Nations Sustainable
Development Goals is to achieve universal health
coverage - a healthcare system that provides access to
quality health-care services without financial risk. The
UN specifically points to access to affordable essential
medicines and vaccines.
As a major distributor of all these products in Asia,
we’ve been working hard to address this issue by boosting
temperature-controlled warehouse storage capacities to
ensure space and products are readily available across the
region. Of our total storage capacity of 310,000 pallets,
we have a cold room capacity of 15,500 pallets. This will
soon increase with our new warehouse being built in the
Philippines and Thailand this year.
Our Distribution Centres (DCs), supported by a
network of branches or sales offices, are strategically
located to perform distinct roles nationally and regionally.
Each DC has various levels of planned redundancies in
systems and equipment to ensure sustained delivery of
critical services under extreme conditions, like pandemics.
Additionally, our continuity procedures enable us to
be agile and responsive in urgent times. It includes
monitoring the situation closely, assessing risks, keeping
key groups informed and following a carefully prepared
action plan to ensure we provide quick and appropriate
responses to the unfolding situation.
Our eZCooler makes the delivery of temperature-
sensitive products cost-effective and safe. With vacuum
insulation panels, the eZCooler does not require an
external energy source to maintain a stable storage
temperature for lengthy periods. It extends the holding
time of the medicines from two to five days, maintaining
product integrity and patient safety. This provides peace
of mind for patients, doctors and clients, even when
products are being delivered to remote parts of Asia.
Moreover, as the eZCooler is reusable it greatly reduces
emissions and costs to get much needed medicines to
some of the most remote parts of Asia.
WWW.ZUELLIGPHARMA.COM
16

Leveraging technology for better health

The WHO estimates that about 20 to 40% of total
healthcare resources are wasted annually due to
inefficiency. Zuellig Pharma has invested heavily to build
a digital infrastructure on our distribution foundations
so as to gain benefits that technology can bring to our
operations.
Our Data Analytics ZiP platform provides data
analysis and custom solutions that provide clients with
real-time actionable insights on treatment management,
pricing and healthcare trends. It also provides an
intelligent way for us to optimize warehouse space
and distribution schedules so as to promote efficiency
throughout our supply chain.

Leveraging AI and Cloud technology

We also invest in start-ups that are making healthcare
more accessible and affordable. Klinify employs cloud-
based technology to help doctors manage their clinics
The WHO estimates that more efficiently. To date, it has helped over 1,000 doctors
in Malaysia migrate to electronic records, making it easier
about 20 to 40% of total to access patient information and allowing patients to

healthcare resources provide self-tracking data for better health outcomes.

Sensely, is an AI-powered virtual nurse chatbot, that turns
are wasted annually static content into natural conversations for patients. It
helps healthcare providers engage patients in an effective
due to inefficiency. and scalable way which lowers the cost of healthcare.

making healthcare more accessible

 17

Promoting adherence
50% of patients do not take their medicines as prescribed,
which often require more expensive interventions down
the road. MedAdvisor, a digital medication management
platform, connects patients to pharmacies to remind and
educate them about disease management. The platform
currently has 2 million users in Australia and is being
launched in the Philippines and Malaysia.
Our CareConnect team has prioritised the
development and refinement of our digital platforms to
cater for more patient programmes. One digital platform
that we are channelling efforts into is our i-Switch+ app,
which aims to improve affordability by keeping records
of chronic patients’ drug purchase and dispensing a free
box with each one purchased. It also allows doctors to
monitor their patients, ensuring patients stick to the
course of their medications.

Partnering with governments

Beyond our daily operations, Zuellig Pharma is increasing
dialogue with members of the healthcare industry and
government, to work towards a unified system that
makes healthcare more accessible to the communities
that we serve. As we move towards a more
To date, we have worked with governments in collaborative healthcare
all our markets in various ways. In Vietnam, we donated ecosystem, we’re always on
US$600,000 worth of eZCoolers to support the quality the lookout for like-minded
of their cold chain in transporting vaccines and other partners who we can work with
temperature-sensitive medicines. During the outbreak to improve health outcomes for
of COVID-19, our team worked around the clock as the communities we serve.
we partnered with the Ministry of Health in Singapore
to deliver surgical masks to front line medical staff Please get in touch with any
islandwide. Our Cambodia team also partnered with of our offices if you would like
PanTheryx, Inc. to donate 12,000 doses of DiaResQ - to find out more, our contact
an anti-diarrheal nutritional product - to the National list is available at the back of
Pediatric Hospital in Phnom Penh. this magazine.

WWW.ZUELLIGPHARMA.COM
18

Sustainability
at Zuellig Pharma
TOWARDS A HEALTHIER FUTURE FOR ASIA

Making healthcare more accessible in Asia has underpinned Zuellig Pharma’s

business throughout our hundred year history and has seen us grow to become
one of the leading providers of healthcare services in the region.

T
he United Nations (UN) defines sustainability
as “meeting the needs of the present without
compromising the ability of future generations to meet
their own needs”. Our approach to business has always
adopted a similar mindset of looking beyond immediate needs
to consider the long-term future of our stakeholders. In 2019,
we embarked on a journey to extend this philosophy and make
sustainability an integral part of the way we run our business. Materiality analysis with 45 internal and
external stakeholders

Identified champions from leadership team to

In line with the UN’s Sustainable Development Goal 3 for Good
Health and Well-being, our vision is to build a healthier future for
Asia by Improving Health Outcomes, Nurturing Talent, Respecting
the Environment and Setting the Highest Standards of Integrity.
A highlight of our journey so far was joining the UN Global
Compact (UNGC) in 2019, where we committed to implementing
drive workstreams across 22 material issues
Joined Business for Social Responsibility (BSR)
Healthcare Working Group
Set roadmaps for the future, with goals, targets
and action plans for each material issue

the UNGC Ten Principles in our business. In 2020, we were also

awarded the Silver Medal by EcoVadis, placing us among the top
Joined the EU-ASEAN Business Council
25% of companies assessed by the sustainability ratings specialist
Sustainability Advocacy Group
and among the top 3% of our industry.
Became a member of Green Freight Asia

Within this dedicated sustainability section, we outline our

sustainability framework (p19), material issues under each pillar
and examples across our markets (p20-p23). We also share about
work with our dedicated regional charity partner (p24) and our
approach to sustainable procurement (p25). We hope this will give
you a clear picture of the vision we have for sustainability and how
we are going to achieve it. We look forward to collaborating with
our clients, customers and partners on this journey.
Joined the United Nations Global Compact (UNGC)
Held our first workshop on fighting modern
slavery with The Mekong Club
Published our inaugural UNGC Communication
on Progress
Awarded EcoVadis Silver Medal 2020

making healthcare more accessible

 19

Our Sustainability Through a materiality analysis with internal and external stakeholders,
we identified 22 material issues we could positively impact. These were shaped
Framework into four pillars, which form the foundation of our approach towards sustainability.

PURPOSE SUSTAINABILITY VISION

Making Healthcare Building a healthier future for Asia with our
More Accesible Clients & Customers

Improving Nurturing Respecting

Health Outcomes Talent The Environment

• Access to Healthcare • Talent Recruitment, • Climate Resilience

Development & Retention
• Affordability • Climate Change Mitigation
• Workplace Health & Safety & Energy Efficiency
• Community Engagement
• Employee Wellbeing • Responsible Waste
• Preventative Care Management
• Employee Engagement
• Enabling Healthcare • Environment Compliance
Professionals • Diversity & Inclusion

Setting The Highest Standards Of Integrity

• Product Quality & Security • Data Privacy & Security

• Counterfeit Products • Public Policy

• Parallel Trade • Responsible Sourcing

• Bribery & Corruption • Responsible Sales

& Marketing

WWW.ZUELLIGPHARMA.COM
20

The Singapore team

performed for patients
and staff at Changi
General Hospital and KK
Hospital to share the joy of
music and show support,
as part of the team’s 80th
anniversary milestone
and the Sing’Theatre
365 Days of Music@
Improving SingHealth programme.

Health Outcomes
For the past three years,
we have supported nursing
scholarships in Myanmar
to build a pipeline of
healthcare talent in the
country. The scholarship
provides aspiring nurses
Access to Healthcare: Making healthcare with complete funding for
more accessible is our core purpose and at a four-year course at
the heart of our operations. We enable access selected universities.

to medicines through warehousing and

logistics services, including innovative last In partnership with B. Braun
Group, we donated 12,500
mile solutions that bring vital medicines to
IV solutions and devices
remote populations. to the Angkor Hospital
for Children during the
Affordability: We seek to reduce the overall cost dengue outbreak
of healthcare. CareConnect makes the supply in Cambodia.

chain more efficient through tailored payor

and disease management programmes. It also
supports over 200,000 patients under patient
access and instalment payment programmes,
which provide discounted medications or
redemption offers.

Community Engagement: Zuellig Pharma

has numerous programmes to support our
employees, partners, patients and local
communities. Where possible, our efforts
encourage healthy behaviours, increasing
disease awareness or access to healthcare.
Preventative Care: We are developing
programmes to ensure that people in Asia
have access to affordable vaccines, including
our employees. We also prepare for
outbreaks by ensuring patients have quick
access to treatments.
“Some of the poorest communities in Asia are
struggling to access quality healthcare, including
receiving much-needed treatments and vaccines.
The region is also battling a rise in complex
lifestyle diseases that are increasing the cost of
healthcare. Strong partnerships with our clients
and customers will accelerate our collective
impact in building a healthier future for Asia.”

Enabling Healthcare Professionals:

Access to basic healthcare expertise is a pressing
concern in emerging economies, especially TOM VANMOLKOT
to pharmacists who are often underserved. EXECUTIVE VICE PRESIDENT
Harnessing our reach, we will invest in training DISTRIBUTION & CLIENT SERVICES,
and educational solutions for pharmacists so they PILLAR LEAD OF IMPROVING
can provide the best advice to support patients. HEALTH OUTCOMES

making healthcare more accessible

 21

“Our 12,000 employees and suppliers work tirelessly

every day to bring medicines to those who need
it most. We want to focus on creating the right
environment to attract, develop and engage a diverse
workforce for the sustainable future of our business.”

Nurturing
Talent
MOHD FAUZI WAHAB
VICE PRESIDENT, HUMAN RESOURCES,
PILLAR LEAD OF NURTURING TALENT
Talent Recruitment, Development &
Retention: We provide both on-the-job
training opportunities and initiatives like our Our Hong Kong Team received
Young Talent Programme for rising stars and the Caring Company award
the Advanced Management Programme (in from The Hong Kong Council
of Social Service for the fifth
partnership with Singapore Management
consecutive year. The award
University) for our management team. was given in recognition of
good corporate citizenship and
Workplace Health & Safety: We uphold the employee wellbeing initiatives,
highest standards of operational excellence in which included “Bring Your Kids
to Work” day, complimentary
our facilities and offices. On top of our robust
health checks and a counselling
workplace health and safety programme, we hotline for employees.
are developing a risk management strategy to
attain the ISO 45001 Occupational Health and Korea employees took part in
the fight against breast cancer
Safety Certification, an international standard
by registering more than 3,400
to prevent work-related injury and ill health. runners across the five-city
Pink Run event. The event was
Employee Wellbeing: Our Human Resources organised to raise awareness
teams take a holistic approach in managing and support for the Korea Breast
Cancer Foundation.
physical and mental wellbeing, ensuring all
employees have support when needed.

Employee Engagement: As a regional

company with a variety of roles, Zuellig
Pharma is building personalised approaches
to developing fulfilling careers for our team.
This will be supported by competitive pay,
workload and managerial support.

Diversity and Inclusion: We believe in

harnessing capabilities from the widest pool
of talent. Our diversity initiatives extend
throughout our people practices from
recruitment to compensation, and promotion
to ensure representation at every level.
Employees complete annual diversity training Our Distribution team in Thailand participated in a “Step Challenge” from March to July 2019 to live a
as we continue to improve our awareness on healthier life. The challenge saw employees aim for regular exercise by clocking at least 10,000 steps daily,
this topic. while ensuring adequate water intake and sleep.

WWW.ZUELLIGPHARMA.COM
22
Respecting
The Environment
Climate Resilience: The region we operate in is
extremely vulnerable to natural disasters. Our
ability to distribute life-saving medicine in times
of crisis has a direct and important impact on
patient lives. Zuellig Pharma works closely with
FM Global to identify and mitigate risks to our
facilities, so that our business can prepare for
and recover quickly from climate impact.
Climate Change Mitigation & Energy Efficiency:
Zuellig Pharma is committed to significantly
reducing its carbon footprint by using
renewable energy and making our transport
more efficient. We are a member of Green
Freight Asia, an industry network focused on
improving fuel efficiency, reducing carbon
emissions and lowering logistics costs across
the entire supply chain.
Responsible Waste Management: When
expired medicines are discarded like other
waste, it can be harmful to the environment
and public health. While we do this safely, we
are also piloting ‘collect back programmes’ for
proper disposal at the consumer level. We also
have programmes to reduce and manage waste
in our facilities.
Environmental Compliance: We operate in an
environmentally conscious way, according to the
diverse regulations of our markets, and we want
to be a catalyst in accelerating environmental
progress for the rest of the healthcare industry.
We are in the process of updating the standards
we aim for, which includes helping our markets
to comply with international certifications such
as ISO 14001.
making healthcare more accessible
“Climate change is a reality that not only affects health
outcomes, but also directly impacts our mission of
making healthcare accessible to the communities we
serve. We believe that we have an ethical responsibility
to protect the environment and comply with
environmental laws and regulations.”
MAIKEL KUIJPERS
EXECUTIVE VICE PRESIDENT, PHILIPPINES,
PILLAR LEAD OF RESPECTING THE
ENVIRONMENT
Environmental considerations
were placed as a top priority
during the building process of
MDI’s new National Distribution
Centre, which aims to be LEED-
certified. Measures include a
focused investment in clean
energy technology such as solar
roofs and LED lighting.
Volunteers from our ZPC
team have been participating
in a sustained tree planting
programme in Cebu since
2017, to root for a healthier
environment. The programme
aims for the reforestation
and rehabilitation of forest
cover within the Central Cebu
Protected Landscape.
Taiwan employees set a
collective goal to reduce their
carbon footprint by reducing
plastic use, having meat-free
days and office-wide lights off
Earth Hour at noon daily. In one
year, these actions will have the
same positive effect of 320 trees
absorbing carbon dioxide.
As part of our focus
on Responsible Waste
Management, we have replaced
delivery cartons with reusable
plastic totes for customers
within the Kota Kinabalu area
in Malaysia.
 23

Zuellig Pharma donated

US$600,000 worth of
eZCoolers and trained
200 provincial healthcare
professionals on Good
Storage Practices for cold
chain supply management
in Vietnam.

Setting The
Highest Standards We are the only company
within the healthcare industry
Of Integrity in Taiwan and Indonesia
to attain the prestigious
ISO 27001 certification for
outstanding procedures and
controls in data security and
Product Quality and Security: We operate a
information systems.
robust quality management system that ensures
product integrity, product security, patient
safety and a vibrant culture of quality. We
We operate the largest
continually develop systems and innovations to distribution centre in
remain leaders in this area. Indonesia with three
temperature - controlled
Bribery and Corruption: We have a strong Anti- environments. The
distribution centre is Good
Bribery and Corruption programme to prevent,
Distribution Practices certified
detect and respond to instances of bribery and and complies with FM Global
corruption. Our Compliance team conducts standards, which minimises
audits to identify potential risks and ensures risks of disruption.
employees and suppliers adhere to the highest
ethical standards.

Counterfeit Products: We are developing
traceability solutions that empower healthcare
professionals and patients to detect counterfeit
products across Asia. These include eZTracker,
a mobile-app that leverages blockchain to
enable users to trace medical products to their
legitimate manufacturer and country of origin.
Parallel Trade of Products: The unauthorised
cross-border sale of medicines threatens patient
accessibility and drug quality. Through eZTracker
and other channels, we are addressing parallel
trade across Asia and increasing its visibility to
tackle it effectively.
Data Privacy and Security: We prioritise
protecting our clients and customer data by
continually developing robust cybersecurity and
data privacy programmes to respond to this
ever-evolving landscape.
Responsible Sourcing: We are committed
to protecting the environment, procuring
ethically, promoting fair labour practices and
journeying with our suppliers to minimise
environmental impact.
“The foundation of our business has always been built upon
us operating at the utmost levels of integrity. Our clients
trust us to protect their products, reputation, and data.
We do this by ensuring the integrity of the supply chain
through safeguarding the quality and security of medicines,
detecting counterfeit and grey market products, combatting
corrupt behaviour and safeguarding data we hold.”
Responsible Sales & Marketing: Healthcare
companies are pivotal in helping the public
make informed decisions on medicine usage.
We contribute by ensuring adverse events and
product comments are captured, analysed and
acted on as appropriate.
Public Policy: Given our established position, we
believe in supporting Asia’s governments to build TIMOTHY HUI
a healthier future for their communities. We are GENERAL COUNSEL &
developing a public policy framework to unlock the CHIEF COMPLIANCE
full potential within healthcare reform, population OFFICER, PILLAR
health, healthcare financing and support, disease LEAD OF SETTING THE
management, and the use of data and analytics to HIGHEST STANDARDS
guide policy. OF INTEGRITY

WWW.ZUELLIGPHARMA.COM
24
Dedicated
Charity Partner
ACTION4DIABETICS
Action4Diabetics (A4D) was set up in 2015 to transform
the lives of young people diagnosed with Type 1
Diabetes (T1D) in South-East Asia.
T1D is an incurable condition which could be fatal if
left untreated. Today, the charity cares for close to 400
T1D patients across the region. 95% of these children
rely on A4D’s programmes for survival as their families
are not able to afford or access medicine or medical
supplies within the country. A4D provide essential
medicines and developmental support like diabetes
family camps, scholarships, and clinic programmes.
They also engage doctors in under-resourced hospitals
on T1D management.
Partnership
Zuellig Pharma has been a corporate sponsor of A4D
for the past 3 years. Through our partnership, we have
found different ways to support their cause and make a
meaningful difference to the lives of these patients and
their families. In early 2019, we also signed up to sponsor
14 children as part of their Sponsor-A-Child programme.
This covers all costs for essential medicines, blood
glucose monitors, transportation to and from clinics for
checks and education for their families and carers.
making healthcare more accessible
Raising funds
COVID-19 led to the cancellation of A4D’s fundraising
events, posing a severe risk to the lives of beneficiaries. To
support these children, we organised the #Mission4Type1
Asia Virtual Challenge.
Nearly 2,000 employees and clients virtually ran,
walked and cycled a total distance of 39,604km, amounting
to US$40,000 in donations from Zuellig Pharma.
Together with an emergency US$25,000
contribution to the charity in April, and individual donations
gathered during the challenge, we raised a total of
US$89,500 which has provided all 450 children under A4D’s
care with access to critical treatment for five months.
Equipping youths
A4D organises regular ASPIRE workshops to equip
young adults who have T1D with the life skills and self-
confidence. Harnessing our internal talent for long-term
positive impact, David Cheah, our Corporate Head of
Organisational and Talent Development, consulted with
A4D and developed a tailored learning programme for
the workshops.
Looking ahead
We look forward to working closely with A4D to improve
the health outcomes of these children through the various
initiatives, and ultimately help provide a healthier and
happier future for them. For more information and
to partner with A4D, please reach out to their team at
www.action4diabetics.org.

SPOTLIGHT ON
Sustainable
Procurement
As many companies start to think critically about
how to integrate sustainability throughout their
supply chain, there has been an increased focus on
the concept of sustainable procurement. It is largely
defined as practices that strive to have a positive
environmental, social and economic impact across the
purchasing and supply management lifecycle, while
upholding company needs for cost efficiency and
security of critical supply.
Our approach
Zuellig Pharma has developed a strong reputation for
integrity and impact over the past century. This role
was built on the seamless collaboration between our
employees and the suppliers. We wanted to apply the
same high standards of collaboration with our partners
when it came to journeying towards a healthier future.
Our procurement team ultimately aims to be a
force for good, educating our suppliers on the need for
sustainability, while promoting supplier diversity, equality,
and inclusion. As a priority, we will address environmental
challenges by minimising pollution, emissions, and energy
consumption. Secondly, we commit to fair labour practices,
including adherence to workplace health and safety,
minimum labour rates and wages, and specific country
regulations. Lastly, we proactively seek and encourage
sustainable innovation with our key partners and clients.
25
Driving responsible sourcing in Asia
In Asia, Zuellig Pharma works primarily with local
suppliers to make healthcare more accessible to
communities. While some of our smaller local partners
will not be able to comply immediately with all
sustainability criteria, we take an inclusive approach
by registering their willingness to comply with our
requirements. We then work with them on a phased
roadmap to achieve shared goals. For instance, we
are collaborating and bringing our key suppliers up to
the required standards, through Health, Safety and
Environment and ecological awareness training.
We started laying the foundations of our
sustainable roadmap by establishing a Global Sustainable
Procurement Policy and Supplier Code of Conduct. In
coming up with these policies, we worked very closely
with our suppliers and internal buyers, to ensure that
policies set would be highly relevant and impactful. This
helped us to balance sustainability and secure supply
while building up our suppliers.
It is important to recognise that sustainable
procurement is a journey. Zuellig Pharma has a vision
of where we need to get to and an action plan to
do so. Every day we are teaching ourselves and our
supply base about the importance and advantages of
sustainability. We look forward to continuing on our path
of empowering local communities through sustainable
procurement practices.
Reach out to our
Sustainability Team
at Sustainability@
zuelligpharma.com
if you would like to
partner with us on
any of our four key
sustainability pillars.
WWW.ZUELLIGPHARMA.COM
26

T
he global cold chain market is poised
to grow 15.1% in the next five years
to reach approximately USD$447.50
billion by 2025. One of the driving
forces behind this growth is that
the majority of pharmaceutical products require
temperature-controlled storage.
“Currently, more than 80% of the
pharmaceutical products we are distributing require
temperature management solutions to remain
effective. This requirement continues to grow with
the expanding range of biopharma products, such as
biologicals, biosimilars, cell and gene therapies, that
are entering the supply chain,” said Brett Marshall,
Corporate Head of Quality Assurance Zuellig Pharma.
The efficacy of today’s higher value and
structurally more complex drugs can be destroyed
through a single break in the cold chain. The
integrity of controlled room temperature products
can be impacted through inconsistent environmental
conditions during distribution. While a weak link in
the management of temperature-sensitive clinical
trial materials can impact study outcomes and lead
to extremely costly delays in bringing new products
to the market.
These challenges, along with the rising
complexity of global supply chains and
increasingly stringent regulatory governance,
make the management of temperature-controlled
environments throughout the pharmaceutical
industry a fundamental capability that needs to be
established and rigorously maintained.

making healthcare more accessible

 27

ALL
A BOARD

cold
TH E

chain
Keeping the temperature just right
WWW.ZUELLIGPHARMA.COM
28
According to the World
Health Organization,
more than 50%
of all vaccines
manufactured in the
world are wasted each
year; a significant
proportion includes
those destroyed
during the storage and
delivery process.
making healthcare more accessible
Going Live
The global Biologics market is expected to
reach USD$625.6 million by 2026, with an
annual growth rate of 11.9% from 2018. A
similar growth rate is expected of the global
specialty drug distribution from 2019 to 2025,
which is predicted to reach US$1580 million
by the end of 2025.
Biologic pharmaceutical products
have much stricter handling requirements
across a range of temperature-controlled
environments. Failure to adhere to these
requirements at any point in the drug’s
lifecycle can impact patient safety or diminish
product availability and supply, which results in
significant waste and supply chain disruption.
We are unfortunately all too familiar
with the global need for vaccines especially
during life-threatening outbreaks like SARS, climate is hot and transportation infrastructure
H1N1 and more recently, COVID-19. Vaccines is limited outside of capital cities.
continue to be one of the most common To mitigate this, we use temperature
types of biologic drug that requires handling monitors, sensors and track and trace systems
at temperatures between 2°C - 8°C to along our entire supply chain to maintain the
maintain efficacy and ensure patient safety. integrity of the drugs we transport every day.
Cold chain integrity is not just important Reports are generated at the end of a delivery
to get vaccines to patients quickly and to confirm no temperature excursions
efficiently, even at the early point of testing, occurred. Soon, real-time monitoring will pair
waste due to temperature excursion could with the ability to provide instant alerts if
delay studies and the introduction of a new temperature trends deviate beyond the safe
treatment or drug. range so that immediate remedial action can
be taken.
Investing in our infrastructure Similarly, the eZCooler with its
To cope with this issue, the industry has phase-change coolants and vacuum insulated
invested significantly in new systems and panels represents a significant investment
capabilities to mitigate the risk of temperature
excursions. These range from sophisticated
in packaging technology. The packaging
system not only provides extended retention
temperature management systems in capability and has a lifetime of four years, but
warehouses, to packaging like the Zuellig is also 100% recyclable.
Pharma eZCooler system that keeps drugs at Investment in a more sophisticated
the right temperatures for up to five days. This supply chain infrastructure can be costly,
last mile is critical to the integrity of the supply but the financial and social cost of non-
chain, especially in Southeast Asia where the compliance is much higher.
 29

How we help
Zuellig Pharma provides our clients with an
established capability for a temperature-
For more information
controlled ecosystem composed of world-
on how we
class warehousing facilities, packaging
manage cold chain
and temperature monitoring systems,
infrastructure
and delivery infrastructure. We pride
and resources,
ourselves on our commitment to quality
please reach out
and maintaining product integrity, through
to Brett Marshall,
practices that meet international regulatory
Corporate Head of
standards. We are also certified compliant
Quality Assurance
for Good Storage and Distribution Practice
at bmarshall@
(GSDP), Good Distribution Practice (GDP),
zuelligpharma.com.
Good Manufacturing Practice (GMP) (for
secondary repackaging) by an external body, Having supported over 2,200 clinical
British Standards Institution (BSI), and have trials, our network of local and central depots
passed multiple Good Practice (GxP) audits has the knowledge and experience to provide
by clients on an annual basis. a one-stop-shop for clinical trial support. This
Our Specialty Solutions Group enables sponsors to customise their clinical
maintains a network of 14 clinical trial supply chain specific to each study, taking
depots across Asia, offering integrated into account regulatory requirements, risk
storage, distribution, returns and aspects, target shipment turnaround times,
destruction, re-labelling and a comparator and geographical focus, to balance study
drug-sourcing service. objectives against cost.

WWW.ZUELLIGPHARMA.COM
30

How we prevented a
LOGISTICAL
LOCKDOWN
to our supply chain
The global COVID-19 pandemic has caused
The global COVID-19 pandemic has caused significant disruptions
chain. With many
in the healthcare of the
supply markets
chain. we serve
With many under
of the markets we
lockdown,
serve under lockdown, it has been crucial for us tothat
it has been crucial for us to ensure ensure that
essential medicines and healthcare supplies continue to be
made available to those who need them the most.
them the most.
Here arethree
Here are threeways
ways that
that have
have helped
helped us ensure
us ensure we continue to
fulfil our mission of making healthcare more accessible during
healthcare
the pandemic. more accessible during this pandemic.

TheglobaCOVID-19pandemichascused
01 Maintaining
ongoing
dialogue with
governments

making healthcare more accessible

 31

W
orking with governments and healthcare In geographically complex countries like the Philippines and
orking with governments and healthcare In geographically complex countries like the Philippines and
associations across the region has always Indonesia, we faced additional challenges. In the Philippines,
associa ons across the region has always Indonesia, we faced addi onal challenges. In the Philippines,
been an integral part of our business. During the suspension of domestic passenger flights presented
been an integral part of our business. During the suspension of domes c passenger flights presented some
this unprecedented time, it has been an even some exceptionally complicated situations. We tackled the
this unprecedented me, it has been an excep onally complicated situa ons. We tackled the
bigger priority to ensure the ongoing movement of critical situation by working with the Philippine Air Force to charter
even bigger priority to ensure the ongoing movement of situa on by working with the Philippine Air Force to charter
medical supplies through various transportation channels – flights to transport medication to the Visayas and Mindanao
cri cal medical supplies through various transporta on flights to transport medica on to the Visayas and Mindanao
land, sea and air. regions. We also partnered with the Philippine Coast Guard to
channels – land, sea and air. regions. We also partnered with the Philippine Coast Guard
transport critical medical supplies to main ports and with the
to transport cri cal medical supplies to main ports and with
COVID-19
COVID-19response
responsemeasures
measureshavehavebeen
beenimplemented
implemented byby Indonesian Army to continue supplying to remote locations in
the Indonesian Army to con nue supplying to remote
country crisis management task forces from
country crisis management task forces from various various min- Papua and more.
loca ons in Papua and more.
istries and departments
ministries and departmentsbeyond Health,
beyond including
Health TradeTrade
including & &
Industry, Transportation, Defence and other Enforcement
Industry, Transporta on, Defence and other Enforcement In
Inother
othermarkets,
markets,including
includingThailand,
Thailand,Malaysia,
Malaysia,Singapore,
Singapore,
bodies.
bodies.Understanding
Understandingthe thedynamics
dynamics ofof
the decision-making
the decision-making Vietnam,
Vietnam, Korea, Hong Kong and Taiwan,we
Korea, Hong Kong and Taiwan, wecollaborated
collaborated with
process at country level allowed us to align
process at country level allowed us to align with with directives
direc ves with
locallocal
and and federal
federal governments
governments* toto ensure
ensure that
that our
our drivers
drivers
and ensured our ability to continue to operate.
and ensured our ability to con nue to operate. and other frontline employees could continue to
and other frontline employees could con nue to carrycarry out
out
their services.
their services.
InInthe
theface
faceofoflockdowns
lockdownsandandmovement
movement control
control plans,
plans, wewe
obtainedexemption
obtained exemp onletiers
le ersfrom
fromgovernments
governments toto allow
allow free- Asthe
As theCOVID-19
COVID-19crisis
crisisevolves
evolvesover
overthethenext
nextseveral
several months,
months,
freedom
dom of movement
of movement foremployees
for our our employees and transport
and transport partners wewill
we willcontinue
con nueour ourdialogue
dialoguewith
withvarious
varioushealth
healthdepart-
partners
across across checkpoints
checkpoints andborders.
and provincial provincial borders.
This ensuredThis
that departments
ments and other andrelevant
other relevant government
government authori
authorities acrosses
the
ensured
all that all land
land deliveries deliveries
of essential of essenand
medicines al healthcare
medicines and
sup- acrossto
region the
beregion to befrom
exempted exempted
specificfrom specific
lockdown lockdown
measures that
healthcare
plies supplies con nued.
continued. measures
may restrictthat maytorestrict
access access
medicines andtohealthcare
medicinessupplies.
and
healthcare supplies.

WWW.ZUELLIGPHARMA.COM
32
46

making healthcare more accessible

02 Driving digital
solutions

making healthcare more accessible


As COVID-19 continues to spread, the
fear of infections and saturated
healthcare systems are driving large
numbers of people online for medical
consultations. To improve access to
health services during the quarantine
D
uring this
period in the Philippines, we are
extraordinary period,
we expedited the
launch of digital
working closely with the Department
platforms in several markets.
This included a fast-tracked
launch of eZRx, an interactive
of Health (DOH) and doctors’
engagement portal for
customers to place orders for
prescription drugs, medical
associations to launch eZConsult, a
devices, or consumer health
products - anytime, anywhere.
telemedicine application. We plan to
eZRx makes up for the inability of
sales reps to visit customers due to
launch in August, working closely
social distancing measures and
lockdowns. The platform ensures that
all orders are fulfilled, while
with our pharmacy partners who wil
maintaining efficiency and product
integrity, and is currently available in
the Philippines, Singapore, and
process the electronic prescriptions
Malaysia with plans to launch in other
markets as soon as possible.
As COVID-19 continues to spread, the
and deliver the medication to
fear of infections and saturated
healthcare systems are driving large
numbers of people online for medical
patients. We aim to replicate this in
consultations. To improve access to
health services during the quarantine
period in the Philippines, we are
other Asian markets as soon as
working closely with the Department
of Health (DOH) and doctors’
associations to launch eZConsult, a
possible.
telemedicine application. We plan to
launch in August, working closely
with our pharmacy partners who will
process the electronic prescriptions
and deliver the medication to
patients. We aim to replicate this in
other Asian markets as soon as
possible.
Malaysia’s largest cloud-based
medical digital assistant for doctors,
has also added several
47
33
WWW.ZfUELLI
eaturesGPHARMA.
to COM
provide up to date information and
insights about COVID-19 trends,
helping doctors to improve patient
outcomes.
Another platform we recently
launched is eZTracker, the first
blockchain-based application in Asia
that allows users to trace a product’s
In addition, we are working closely
origins and authenticity by scanning a
code on the packaging. A BBC
article highlighted a rising trend of
counterfeit medicines due to
with several of our other digital
COVID-19, posing a major threat to
supply chain integrity.
partners – MedAdvisor, Docquity,
With eZTracker, Zuellig Pharma and
the medicine’s manufacturer are
immediately notified if an
Reach52, and Sensely to help them
unregistered product is detected and
can bring this up with the relevant
authorities. This app is currently
scale up their solutions in the markets
available in Hong Kong and as part of
our response to COVID-19, we have
accelerated its launch in the
Philippines to help support the
we serve. All these digital start-ups
country’s mass vaccination
programme and track up to one
million flu vaccine doses.
have developed digital health
Our wholly-owned subsidiary Klinify,
Malaysia’s largest cloud-based
solutions that help tackle COVID-19
medical digital assistant for doctors,
has also added several features to
provide up to date information and
and wil help improve patient
insights about COVID-19 trends,
helping doctors to improve patient
outcomes.
outcomes.
In addition, we are working closely
with several of our other digital
partners – MedAdvisor, Docquity,
Reach52, and Sensely to help them
scale up their solutions in the markets
we serve. All these digital start-ups
have developed digital health
solutions that help tackle COVID-19
and will help improve patient
outcomes.
WWW.ZUELLIGPHARMA.COM
34
48

48

03 Enforcing stringent
on-ground
implementation

making healthcare more accessible

 49
35

49

Since the early onset of the pandemic, our warehouses and offices across the region. Best practices are
teams have been firmly committed to continually being shared with other country operations.
preventing any disruptions to the supply
chains, while taking precautionary measures to The COVID-19 pandemic is unprecedented, and it is still
protect themselves. Our Business Continuity highly uncertain how it will evolve. However, with the
measures we have put in place, jointly with our customers,
Plans have been tested in real time and have
clients and partners, we believe that we are well-placed to
held up well.
see this through.
In Taiwan, our team worked closely with the Taiwan Center
*List of government ministries include: Department of Disease
for Disease Control, and in Malaysia with Ministry of Health,
to implement measures that minimise the risk of virus
Industry (Malaysia), Ministry of Health (Singapore), Ministry
transmission within our premises. This includes
of Health (Vietnam), Ministry of Health and Welfare (Korea),
comprehensive safe-distancing measures and regular
Department of Health (Hong Kong) and Taiwan Center for
communication with employees to ensure compliance. In
Disease Control (Taiwan)
Myanmar, we passed a rigorous inspection conducted by the
Ministry of Labour and Immigration and Ministry of Health
and Sports who visited and inspected our warehouses to
ensure that we are following official guidelines. Lastly, our
teams are constantly reminded to practice safe hygiene and
social distancing through the display of posters in our

WWW.ZUELLIGPHARMA.COM
36

How supply chains

will evolve
IN THE WAKE
OF COVID-19
COVID-19 has had far-reaching
effects on global supply
chains. Supply chains all over
the world have been put to the
test as countries and
businesses battle to effectively
manage disruptions caused by
the pandemic.

Z
uellig Pharma is one of the largest healthcare
services groups in Asia that serves over 350,000
medical facilities. Knowing that our work has a
tremendous impact on the health of many
communities we operate in, our teams across the region have
been innovating and working non-stop to ensure that
essential medicines and healthcare continue to be accessible.

While we have some way to go in our fight against the virus,

we recognise that the management of supply chains will
evolve when the dust starts to settle. Here are some ways we
have identified.

making healthcare more accessible


Strengthening engagement
with key stakeholders
Pandemic response plans and actions
being implemented across the region
involve the collaboration of many
government departments within each
country, all with a common goal to
ensure freedom of movement for
essential products and services.
As lockdowns significantly impact the
delivery of medical essentials, Zuellig
Pharma quickly recognised the need
to maintain ongoing dialogues with
the different stakeholders to align on
supply chain structural needs to
support an effective response.
In the Philippines, we expanded our
range of stakeholders beyond our
usual partner – the Department of
Health. We worked on building
communications with other agencies
involved in the pandemic response
management, such as the ministries
for trade, transportation and defence.
Counting on our capabilities and
strong partnership with the
Department of Health, Zuellig
Pharma’s delivery of life-saving
medication was recognised as an
essential service. Teams were able to
continue with deliveries despite the
widespread restrictions on movement.
37
In times of need, we leveraged our
expertise and capabilities to support
our clients and customers’ supply
chain requirements to the best of our
abilities.
Moving forward, we will see a more
pressing need for businesses to
establish discussion platforms
together with industry associations
and government, for alignment and
engagement to take place and to set
up capabilities to effectively manage
future situations.
WWW.ZUELLIGPHARMA.COM
52
38
Sales
History
10/04/20 04/12/20 07/06/20
Utilising
innovation to build
remote working
capabilities Technology is a cri�cal enabler. With
strict safe distancing measures in
place and guidelines to allow
employees to work from home
whenever possible, teams are no
longer able to be fully present onsite.
This has sparked a stronger need for
digitalisa�on and the development of
remote working capabili�es to ensure
businesses s�ll operate as per normal.
But the digital divide remains,
technologically advanced countries
like Singapore have exis�ng
infrastructure to take the lead, while
less advanced markets need to build
their capabili�es to leverage these
opportuni�es. One way we have
helped in bridging the gap is to have
our Digital Solu�ons team ramping up
the development of technologies for
making healthcare more accessible
Order Approval
use across all our 13 markets. For
example, our online ordering
pla�orm, eZRx, which was recently
launched in the Philippines, Singapore
and Malaysia and accelera�on of
roll-out across the rest of our markets
this year, enables customers to place
and pay for orders of medical stocks
any�me, anywhere. This can be done
without reliance on sales reps to be
present for order and payments
collec�on.
Also, non-frontline staff in Zuellig
Pharma have a host of digital tools at
their finger�ps that facilitate
important business mee�ngs and help
employees in daily discussions,
collabora�on and tasks, and
opera�ons, quality and financial
governance.

Adopting The global pandemic has surfaced
gaps in our healthcare supply chain. It
a risk-based has shown us the importance of
ensuring the resilience of supply
chains and agility, which are key in
approach establishing capabili�es to manage
these disrup�ons, as businesses across
the globe fold and many are faced
with the reality of empty supermarket
shelves and a shortage of hospital
supplies.
We will see a larger focus from
companies in balancing cost against a
deeper understanding of supply chains
and risk when it comes to developing
their medium and long term supply
chain strategy. Material sourcing will
be reviewed, geographic produc�on
capabili�es re-assessed, strategic
inventories iden�fied, late-stage
customisa�on op�ons considered. Our
53
39
teams are trained in risk-based
thinking and have iden�fied a few key
opportunity areas to work on to build
resilience in our business when the
next event occurs.
For instance, many of our teams at
Zuellig Pharma are front liners. They
are working on the ground to ensure
pharmaceu�cals, medical devices and
diagnos�cs are efficiently delivered to
healthcare providers who urgently
require them. It is thus cri�cal to
ensure the health and welfare of these
workers, as they are such a
tremendous resource. To do so, we
need to plan for scenarios with
simula�ons, test them and make
adjustments so we can effec�vely deal
with inevitable future disrup�ons.
As we come together to overcome
COVID-19, it is not a ques�on of if, but
when the next one will come along.
We will need to be as prepared as
possible in terms of bolstering our
strategies, priori�sing our
communica�ons as well as trainings
and arrangements with various
stakeholders so that we are
well-equipped for the future.
WWW.ZUELLIGPHARMA.COM
40

Paving the
Way for
Ageing
Population

A
sia will be home to more than 60% of
the world’s population that is aged over
65 by 2030. Increasing life expectancies
coupled with declining birth rates will
see economies start to buckle under
the weight of their maturity and its associated costs,
especially in healthcare.
Our CareConnect business has been building
sustainable solutions that will see people through all
stages of life. The goal is to equip them with tools to
remain healthy, regardless of age. An essential first step
is helping the population protect themselves against
unnecessary infections. It is also key to ensure that the
population can afford the interventions they need and
adhere to programmes that improve health outcomes.

making healthcare more accessible

 41

WWW.ZUELLIGPHARMA.COM
42
Prevention
Up to 650,000 people die globally from seasonal
influenza each year. This is why vaccinations are key to
protecting the immune system particularly among high
risk demographics. Minor infections among the elderly
can lead to complications that cause long-term illness,
hospitalisation, and even death.
Despite the significant benefits of vaccination,
awareness can be a barrier to immunisation,
particularly when the population lacks knowledge or
has misconceptions about its benefits. Accessibility to
get vaccinated also impacts the uptake of vaccination
programmes.
Zuellig Pharma has administered over 290,000
doses of vaccines since establishing a partnership with
Mercury Drug Store in 2016 with the Philippines. We
create in-store awareness activities and provide free
vaccine administration services in more than 200 stores
across the country.
We also hope to drive improved access to vaccines
through mass vaccinations at work. Since 2011, we have
helped over 1,500 companies and institutions manage
and administer over 1 million doses of vaccines. Our
services include online registration and ordering, delivery
of products, administration of vaccines, data and insight
reports to evaluate effectiveness, as well as options for
on-going patient management programmes.
PAYOR SERVICES
Presence in 3 countries with Working with
close to 11mil members: more than
400,000 2.9 mil 7.6 mil
PHILIPPINES THAILAND MALAYSIA
7500
CORPORATES
making healthcare more accessible
Affordability
Financial hardships can dissuade patients from getting the
healthcare they need. Some specialty drugs and treatments
can run up bills close to US$100,000 per patient annually.
Even patients on medication for chronic diseases, that
are without exorbitant price tags, can have their finances
dampened due to its prolonged maintenance phase, which
is often a lifetime medication commitment.
Zuellig Pharma has been working with
organisations and hospitals to make medicines more
affordable for patients. We work with drug manufacturers
and license holders on patient affordability programmes
to provide patients with subsidised offerings on specific
medicines. Most recently, some patients were notified on
their eligibility for subsidised medications via i-Switch+ or
eZPAP+, a suite of newly launched applications which logs
patients’ purchase histories. Since its launch in December
2019, more than 150 enrolled healthcare professionals
have started using i-Switch+ with approximately 1,000
patients in Malaysia.
Zuellig Pharma also carries out simple financial
means-testing to identify and segment patients based
on an affordability index to ensure each patient can
afford the healthcare they need. We also work with drug
manufacturers and license holders to provide patients with
interest-free payment support schemes, allowing them to
pay for their medicines in instalments. In Singapore, we
have partnered with two of the country’s largest banks to
introduce 6 to 12-month interest-free instalment payment
plans to make treatment more affordable.
42
Process more than
INSURANCE
US$500
COMPANIES MILLION
worth of claims
every year
 43

PATIENT i-SWITCH+
ADHERENCE
PROGRAMMES Launched in More than More than

Served more than

Malaysia in
1,500 150
20,000 DEC PATIENTS
to date MEDICAL
PATIENTS 2019 PROFESSIONALS

Management Leveraging data to improve patient

Keeping people committed to prioritising their health and programmes
treatments involve continual support. The healthcare sector generates a huge amount of
Zuellig Pharma offers educational programmes, data that can be harnessed for better health outcomes.
which aims to modify the beliefs and behaviours With the opening of the Zuellig Health Solutions (ZHS)
associated with treatment adherence. By providing innovation centre in 2017, we established a data analytics
educational material and communicating with patients team to translate these data sets into actionable insights.
across multiple mediums, patients are constantly These have been used to develop screening programmes
reminded of the importance of adhering to their to identify pre-diabetic patients, helping them to delay or
treatments, supported through potential initial side avoid the onset of the disease by encouraging healthier
effects and educated on proper medication delivery lifestyles.
where necessary. We also support physicians and nurses Moses added, “We’re studying trends between
by sharing key information so they can monitor their patient behaviours and interventions based on data
patient’s progress. we’ve collected over years of operations. We look
Additionally, through i-Switch, patients can keep forward to discovering new ways to support our clients
track of their health by recording various health metrics. and customers to make healthcare more accessible and
The app syncs with health and fitness trackers to provide affordable for patients.”
users with the ability to constantly monitor their health all
day long. Patients are motivated to make better lifestyle
choices that can enhance their progress.
Moses Hee, Zuellig Pharma Senior Vice President
CareConnect said, “Challenges of patient adherence can
range anywhere from affordability to physical access, even
to less tangible ones like frustration and confusion with
the dietary restrictions of certain medications. By keeping
in close contact with patients and providing access to
educational materials that change their perspective
towards treatments, we have become running mates with
them along their journey to recovery.”

WWW.ZUELLIGPHARMA.COM
44

Springboarding
The
Next
Leap
DOCTORS
EMPOWERING DOCTORS

Docquity supports conti nual medical

Since identifying digital innovations
as a must-have for the business,
educati on and networking for doctors.
There are currently more than 100,000
users across Indonesia, the Philippines,
Thailand and Malaysia.

Zuellig Pharma has supported Klinify is a digital assistant for doctors,

and launched a growing list of
applications designed by both in-
house and start-up teams across
Asia. Here are some highlights of
projects we have worked on so far,
with more to come in the pipeline:
which unlocks the power of real-world
medical data. Close to 1,000 GPs use it to
support over 300,000 pati ent visits every
month in Malaysia.
Sensely is an artificial intelligence-
powered virtual conversational chatbot
(virtual nurse) that facilitates access to
high quality and affordable healthcare
by turning static content into natural
conversations.

making healthcare more accessible


PATIENTS
HELPING PEOPLE STAY HEALTHY
i-Switch+ supports patient access and
affordability programmes by helping
patients manage the cost of their long
term medication. The tool enables HCPs to
easily track patients’ rebates and provides
alerts when they are entitled to free
medication. It also supports the patients’
journeys by encouraging lifestyle changes
to reduce the risk of chronic lifestyle
diseases. Launched in December 2019,
the platform has more than 1,500 patient
users to date.
ACCESS TO HEALTHCARE IN THE COMMUNITY
Reach52 connects underserved, lower-
middle-class communities to doctors,
pharmacies, insurers and the healthcare
industry to ensure they are receiving
the quality care they need. It does this
by combining an award-winning tech
ecosystem with in-community resources
to improve access to healthcare. The
platform is currently active in the
Philippines and Cambodia.
MAINTAINING PATIENT ADHERENCE
MedAdvisor is a medication
management platform that connects
patients to pharmacies to drive
adherence through reminders and
education. The platform has close to 2
million users in Australia and is being
launched in the Philippines and Malaysia,
followed by Thailand and Indonesia.
IMPROVING ACCESS TO
AFFORDABLE MEDICATION
eZPAP shortens the lead time to administer
free drugs and supports patients by
creating a seamless flow from registration
to delivery. The platform is currently live in
Malaysia, Taiwan and the Philippines.
45
CLIENTS
ACCESS TO MEDICINES
Zyllem helps build and operate complex
logistics networks at a lower cost. It
provides visibility across all logistics
operations, intelligent tracking and
transport route optimisation. The platform
is currently live in Singapore, Malaysia,
Vietnam, the Philippines and Thailand.
ZiP is a powerful set of data tools that
give clients access to real-time market
data, have oversight of operations and
understand customers. With these tools,
data is efficiently extracted and
converted to actionable insights for
better decision making.
eZRx is an online portal that enables
constant connection and engagement
with customers. Through the platform,
customers can order products, make
payments online and arrange returns
seamlessly. Users are also able to track
orders, view account statements and
review purchasing balance to optimise
inventory management.
FIGHTING COUNTERFEITS
eZTracker uses blockchain to drive
transparency in the pharmaceutical
supply chain by authenticating medication
throughout each step - from manufacturing
to our distribution centres, and then from
our distribution centres to clinics and
patients. The application is downloadable on
Google Play Store and the App Store.
WWW.ZUELLIGPHARMA.COM
46

Accelerating
growth with
new players
in healthcare
Fostering partnerships to address industry
pain points and changing needs

WRITTEN BY MAARTEN KELDER,

EVP STRATEGY AND CORPORATE DEVELOPMENT

making healthcare more accessible


A
s an organisation, Zuellig Pharma
recognises the immense value
that passionate and driven
entrepreneurs bring to the table
and we are committed to helping them
scale-up their business. As the industry
grows to include new players, we believe
in taking the right steps to create a
platform that can connect everyone in the
healthcare ecosystem.
We have been working with
HealthTech startups to address some of
the key pain points in our industry. The
healthcare ecosystem is facing mounting
challenges – growing populations in
developing markets, chronic diseases and
ageing in developed markets, lack of access
to healthcare and inefficiencies in healthcare
systems due to silos within the industry.
Innovation and disruption to the
healthcare industry is happening quickly in
completely non-linear ways, and it is crucial
for start-ups and corporations to form the
right partnerships to deliver better care
to the patients that we serve. To keep our
partnerships at their best, we kept these 3
principles in mind:
1
An impactful partnership needs
the best mix of internal and
external support
Innovative ideas, speed and agility are
the key advantages that startups bring to
the table, but they most often lack access
to capital and networks. Corporates can
help to connect new players with the right
industry veterans to scale up. Startup
founders and corporate leaders will have
to champion the cause and pave the way
for others to follow suit. Partnering will
allow both parties to impact the overall
ecosystem in ways that neither could have
done alone.
With Zuellig Pharma’s unique
position in the industry placing us at the
intersection of many players, processes
and transactions, there are plenty of
opportunities for us to forge partnerships
with and between stakeholders. Our job
then is to identify the right mix of internal
and external partnerships from our extensive
network and connect these to the respective
HealthTech solutions we are supporting.
2 With our successful investments
Consider the environment and
invest in the right opportunities
When considering a partnership, it is best
to assess the current ecosystem and ask
if the innovations can be made stronger
by plugging into the corporate’s core
capabilities and infrastructure.
Zuellig Pharma’s unique position in
the industry allows us an overview of the
rapidly changing environment with its pain
points and opportunities so that we can
best determine if a new idea is timely
and suitable.
The startups we invested in were
selected because of their passion and
commitment to our mission of making
healthcare more accessible. By allowing
them to plug into our platform, we hope
to promote efficiency, lower costs and
ultimately improve patient outcomes.
47
3
It takes time and relentless
determination to make
things work
Change always requires adjustment, patience
and hard work. As a business which has always
upheld a pioneering spirit as one of our core
principles, we know from experience that
patience is needed to see our efforts come to
fruition. With this in mind, we nurture new
partnerships by applying the same level of
rigour and pragmatism that has made us a
trusted partner to our clients.
Already we are seeing progress,
with Zuellig Pharma receiving one of the
four prestigious ‘Information Visionary’
awards at the second Singapore IDC Digital
Transformation Awards 2019 out of 1,000
entries across Asia Pacific.
combined with the exciting opportunities
that lay ahead, it is an exciting time to be in
healthcare. We must take a good look at the
seeds we can sow today to reap the benefits
tomorrow for the industry and for the
patients that we all care for.
Reach out to Executive
Vice President
Strategy & Corporate
Development Maarten
Kelder at MKelder@
zuelligpharma.com
to learn more about
strategic partnership
opportunities.
WWW.ZUELLIGPHARMA.COM
 The
Blockchain
that Keeps
us Safe
A
ccording to the World Health Organization (WHO), an estimated one
in 10 drugs sold in developing countries is fake or substandard, and
while tens of millions of counterfeit drugs are seized yearly by law
enforcement agencies like Interpol, the problem is still rampant and
causing immeasurable harm.
Naturally, the most commonly targetted drugs are expensive medications
that are in high demand - antibiotics, vaccines, hormones and chemotherapy
treatments. Many of these are too potent, weak or toxic; all of which have
the ability to lead to fatal consequences. Unfortunately, access to specialised
equipment and technology have given counterfeiters and grey market perpetrators
entry to a global marketplace that continues to grow.
Over the past few years, Zuellig Pharma has been working on a blockchain-
based solution to try and address this troubling issue. We recently launched the
eZTracker - the first application in Asia that allows any user to trace a product’s
origins and authenticity just by scanning its packaging. If an unregistered product is
detected, Zuellig Pharma and the drug’s legitimate manufacturer are immediately
notified and can bring this up with the relevant authorities.
The eZTracker is also useful in supporting product recalls. While previous
efforts would have taken weeks to detect and withdraw a defective batch of drugs
from a market, the eZTracker provides an immediate solution which can be used
by numerous users to quickly remove the specific drugs in question.
With the ability to confirm product authenticity in real-time, doctors can
administer drugs with confidence and patients can trust that they’re consuming
legitimate products. The eZTracker also provides information about the medicine,
including expiry dates and storage instructions.

making healthcare more accessible

WWW.ZUELLIGPHARMA.COM
50

The
eZTracker
Journey
PATIENT LAUNCHES
DELIVERY REGISTRATION WAITING AREA CONSULTATION EZTRACKER

Brochures and posters Patient enters clinic Patient views Doctor passes
will be delivered to and registers posters, downloads medicine packaging to
your Clinic. We ask for treatment. eZTracker app. patient for scanning.
for your help in Nurse provides
placing these in eZTracker brochure.
prominent places to
raise awareness.

How to use eZTracker

DOWNLOAD ASK LAUNCH ALLOW SCAN VERIFY

eZTracker eZTracker

Authorised
Allow ÒeZTrackerÓ to
access your camer a

DonÕt Allo w OK

eZTracker: Before consuming Open eZTracker on Click OK to give Tap the eZTracker eZTracker will
Safety in your medication, ask your mobile phone permission for icon and scan show 2 results:
Each Scan your doctor for your eZTracker to access the QR code on
medicine packaging your camera. This is medicine packaging.
for scanning purposes.

AUTHORISED Indicates the packaging originates from the NOT RECOGNISED Please fill in the form in the app to help us
BY EZTRACKER
legitimate manufacturer and is authorised verify your product. Your information will be
to be distributed in your location. shared with the manufacturer for follow up.

making healthcare more accessible

 51

How Blockchain works

SUPPLIER MANUFACTURER DISTRIBUTION CHANNEL

Information uploaded onto blockchain

* Application Program
API* API API Interface (API)
A set of routines,
Ledger + Ledger + Ledger + protocols, and tools for
Database Database Database software applications,
specifying how its
CLIENT NODE ZUELLIG NODE components should interact.

MATCH AUTHORISED
FOUND Allow patients to
receive medicine

APPLICATION
USES
eZTracker eZTracker

PATIENT BLOCKCHAIN
SCANS QR TO DELIVER
Tap to
scan product

CODE OUTCOME

MATCH NOT RECOGNISED

NOT BY EZTRACKER
FOUND Please fill in the
form in the app
to help us verify
Try scanning the QR codes below your product. Your
information will
be shared with the
manufacturer for
follow up.

RELEVANT
AUTHORITIES
NOTIFIED

The eZTracker is available for For more information, reach out to Tristan Tan (TTanz@zuelligpharma.com)
download on the Apple App and Gillian Choo (GChoo@zuelligpharma.com) to find out more about the
Store and Google Play Store. eZTracker and other solutions.

WWW.ZUELLIGPHARMA.COM
52

Our Data Analytics

IN NUMBERS

More than
Data reports
are generated
for
13
countries

1,600 jobs The volume of

data processed
run continuously with the most reports
being produced for from 2018 to
on our serves to 2019 grew by
generate daily The Philippines.
reports. 14.1%.

Close to Zuellig Pharma We optimised at least

66
operates on the
13,000 largest cloud-based
SAP platform
queries in Asia.
process trees
are processed by our for clients
database every day. in 2019.
That’s nearly 10
queries per minute.

The current size of our

data warehouse is

1.8
Petabytes
the equivalent
storage of
1.8 million
CD-ROMs!

The data team has The team has a

doubled from 2018 50:50 male and
to 2019.
female ratio
The youngest
person in the
team is
24
years old!
and is made up of
graduates from diverse
backgrounds, including
Political Science, English
The average age of the team
is 28, the youngest team within
Literature, and Solar Cell
the regional office. Engineering.

making healthcare more accessible

CONTACT US

CORPORATE OFFICE COUNTRY OFFICES

Zuellig Pharma Holdings

47 Scotts Road CAMBODIA PHILIPPINES
#10-00 Goldbell Towers Frederik Meerhoff Danilo Cahoy
Singapore 228233 General Manager Chief Executive
Tel: +65 6708 8188 Zuellig Pharma Ltd. Zuellig Pharma Corporation
Tel: +848 3910 2650 Tel: +63 (2) 908 2222
Fmeerhoff@zuelligpharma.com DCahoy@zuelligpharma.com
John Graham
Chief Executive Officer
HONG KONG & MACAU Agnes Rafinan
EVP Commercial Solutions
Andi Umbricht Chief Executive
Chief Executive Metro Drug Inc.
Tom Vanmolkot
Zuellig Pharma Ltd. Tel: +63 (2) 802 7575
EVP Distribution & Client Services
Tel: +852 2856 3632 ARafinan@metrodrug.com.ph
Aumbricht@zuelligpharma.com
Moses Hee
SINGAPORE
SVP CareConnect
INDONESIA Yan Ann Tan
Christophe Piganiol Chief Executive
Ray Azurin
President Director Zuellig Pharma Pte. Ltd.
SVP Sustainability & Government Affairs
P.T. Anugerah Pharmindo Lestari Tel: +65 6546 8188
Tel: +62 (21) 345 6008 Yatan@zuelligpharma.com
Maikel Kuijpers
Cpiganiol@zuelligpharma.com
Area Director Philippines
TAIWAN
KOREA John Chou
Giuseppe Leo
Erwan Vilfeu Chief Executive
Area Director North Asia & Singapore
President Zuellig Pharma, Inc.
Zuellig Pharma Korea Ltd. Tel: +886 (2) 2570 0064
Yves Hermes
Tel: +82 (2) 2006 0600 Jcchou@zuelligpharma.com
Area Director Southeast Asia
Evilfeu@zuelligpharma.com
THAILAND
Alan Ong
MALAYSIA & BRUNEI Pucknalin Bulakul
Chief Executive Clinical Reach Chief Executive
Louis-Georges Lassonnery
Chief Executive Zuellig Pharma Ltd.
Tristan Tan Tel: +66 2656 8221
Zuellig Pharma Sdn. Bhd.
VP Data & Analytics PucknalinB@zuelligpharma.com
Tel: +60 (3) 5566 2188
lglassonnery@zuelligpharma.com
Brett Marshall
VIETNAM
Corporate Head of Quality Assurance
MYANMAR Marc Franck
Jan Rask Christensen Chief Executive
Robert Kruit
General Manager Zuellig Pharma Vietnam Ltd.
VP Client Development
Myanmar Zuellig Pharma Services Ltd. Tel: +84 (8) 3910 2650
Tel: +(66) 0-2656-9800 Mfranck@zuelligpharma.com
Louis Payet
JanC@zuelligpharma.com
VP Business Development Commercial
Solutions